Many breast cancer clinical trials using immunotherapy combined with chemotherapy or other targeted agents have mostly been in TNBC and HER2+ tumors as these subtypes display the highest immunogenicity (PD-L1+ TIL, PD-L1+ tumor, mutation, neoantigen load, and MHC expression) [34]. The gene discussed is ERBB2; the disease is breast carcinoma.